Accepted for/Published in: JMIR Bioinformatics and Biotechnology
Date Submitted: Sep 12, 2023
Date Accepted: Apr 17, 2024
ChatGPT and Medicine - Together We Embrace the AI Renaissance
ABSTRACT
This editorial paper explores the transformative potential of the generative artificial intelligence (AI) model, Chat Generative Pre-training Transformer (ChatGPT) in the fields of bioinformatics, biotechnology, and medicine, presenting perspectives from both the AI and the physician. The development of such models has signaled the beginning of a new era where complex biological data can be made more accessible and interpretable. ChatGPT is a natural language processing tool with the ability to process, interpret, and summarize vast datasets. It can serve as a digital assistant for physicians and researchers, aiding in the integration of medical imaging data, multi-omics data, identifying patterns in genomic variations, and facilitating the understanding of complex biological systems. Notably, its potential contribution to the field of cancer genomics and precision medicine is discussed. The physician's and the AI’s viewpoint emphasize the value of such AI models in a clinical setting, providing tangible examples of how this could enhance patient care and treatment strategies. The editorial also discusses the rise of generative AI, highlighting its significant impact in democratizing bioinformatics applications for modern medicine. While AI may not supersede healthcare professionals, practitioners incorporating AI into their practices could potentially have a competitive edge.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.